InnoCare (SSE: 688428; HKEX: 09969) is a commercial-stage biopharmaceutical company. Co-founded in 2015 by Dr. Jasmine Cui, who has a rich experience in drug R&D and company management, and Dr. Yigong Shi, a world-renowned structural biologist. InnoCare has built a complete biopharma platform incorporating innovation, clinical development, commercialization and manufacturing. We are committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases.

InnoCare has developed a rich pipeline. Orelabrutinib has been approved for marketing in China and Singapore and has also been included in China’s National Reimbursement Drug List (NRDL). Tafasitamab, in combination with lenalidomide, has been approved for marking in Hong Kong and approved for use in Bo’ao and the Greater Bay Area. Currently, InnoCare has 13 innovate drugs at the clinical stage. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the US.